ClinicalTrials.gg
CompletedNCT07789561Updated Aug 27, 2026

Functional Food Product

An interventional study of pomegranate peel powder 1.5 g and pomegranate peel powder 3 g in Ulcer, Blood Tests and Liver Function Tests, sponsored by University of Lahore. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Feb 2024, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

Background/Objective: This study evaluated the effects of pomegranate peel powder (PPP)-enriched muffins containing 1.5 g or 2.5 g PPP on H. pylori, inflammation, oxidative stress, and gastric ulcer healing in patients with gastric ulcers.

Conclusion: PPP-enriched muffins showed potential as a functional dietary intervention for improving antioxidant and anti-inflammatory status and supporting gastric ulcer healing.

Read the detailed description

Background/Objective: This study investigated the therapeutic potential of pomegranate peel powder (PPP), a polyphenol- and antioxidant-rich ingredient, incorporated into whole-wheat muffins at doses of 1.5 g and 2.5 g for patients with gastric ulcers. The study assessed its potential effects on H. pylori infection, gastric inflammation, oxidative stress, and mucosal healing.

Conclusion: PPP-enriched muffins were evaluated as a functional dietary intervention with potential gastroprotective, antioxidant, and anti-inflammatory properties, supporting their possible role in dietary management of gastric ulcers.

02

Conditions studied

  • Ulcer
  • Blood Tests
  • Liver Function Tests

Keywords

  • Punica granatum,
  • Gastric Ulcer
  • Helicobacter pylori
  • Functional Foods
03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 62 are open to participants now.

This study's enrollment of 88 is above the median of 65 across 291 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

University of Lahore is the lead sponsor of 232 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both male and female patients aged 40-60 years with confirmed Helicobacter pylori infection, verified through stool antigen testing along with elevated pepsinogen I and II levels, were included in the study

Exclusion criteria

Exclusion Criteria:

pregnancy or lactation, history of gastric surgery, and current use of proton pump inhibitors. and use of medication

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    T0: placebo

    wheat muffin

    Dietary Supplement: Whole wheat muffin

  • Experimental
    T1= muffin with 1.5g ppp

    Whole wheat muffin enriched with pomegranate peel powder (PPP=1.5g) + conventional Therapy

    Dietary Supplement: pomegranate peel powder 1.5 g

  • Experimental
    T2= Muffin with 3g ppp

    Whole wheat muffin enriched with pomegranate peel powder (PPP=2.5g) + conventional Therapy

    Dietary Supplement: pomegranate peel powder 3 g

Interventions

  • Dietary supplementpomegranate peel powder 1.5 g

    Whole wheat muffin enriched with pomegranate peel powder (PPP=1.5 g) + conventional Therapy

  • Dietary supplementpomegranate peel powder 3 g

    Whole wheat muffin enriched with pomegranate peel powder (PPP=3g) + conventional Therapy

  • Dietary supplementWhole wheat muffin

    Whole wheat muffin

06

What researchers measure

Primary outcomes

  1. Liver Enzymes

    Time frame: 9 weeks

Secondary outcomes

  1. H.phylori

    Time frame: 9 weeks

07

Study locations

1 site
  • Sana Noreen
    Lahore, Punjab Province 54000, Pakistan
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in May 2024, 2 months.

Of 43 non-industry interventional studies with no phase under Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 64. This study's 2 months is below that.

Counting every sponsor, half of 68 studies reached it within 25 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 27, 2026
StartActual
Feb 15, 2024
Primary completionActual
May 5, 2024
CompletionActual
May 7, 2024
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07789561
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Feb 15, 2024
Primary completion
May 5, 2024
Completion
May 7, 2024
Last update
Aug 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion